[Company Logo Image]

Treatment Experienced Clinical Trials

Protocol	Title
A5115	A Phase II Randomized, Controlled, Pilot Study of Antiretroviral Switch at Lower versus Higher HIV-1 RNA Levels in Subjects Experiencing Virologic Relapse on a Current HAART Regimen
A5126	A Phase II Study of the Predictive Value of Pharmacokinetic-Adjusted Phenotypic Susceptibility (C12h/IC50) on Antiretroviral Response to Ritonavir-Enhanced Protease Inhibitors in Subjects with Failure of Previous Protease Inhibitor-Based Regimens
A5146	A Randomized Controlled Trial Evaluating the Impact of Therapeutic Drug Monitoring (TDM) on Virologic Response to a Salvage Regimen in Subjects with a Normalized Inhibitory Quotient (NIQ) Less Than or Equal to One to One or More Protease Inhibitors
A5165	A Phase I/II Randomized, Double-Blind, Placebo-Controlled Pilot Study of b-D-2,6-Diaminopurine Dioxolane (DAPD) vs. DAPD plus Mycophenolate Mofetil (MMF) in Treatment Experienced Subjects
A431106	A phase 2, Randomized, Double-Blind, Dose-Ranging Study of Capravirine (AG1549) in Combination with Kaletra™ and at least 2 Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Subjects Who Have Failed Antiretroviral Regimens Containing Protease Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors and Nucleoside Reverse Transcriptase Inhibitors
AI455-135	ZEST-QD: A Phase IIIB, Open-Label, Randomized, Multicenter Study Switching HIV-1 Infected Subjects with a Viral Load of <50 Copies/mL on a BID or More Frequent Initial Regimen to a Once Daily Regimen Including Stavudine XR, Lamivudine and Efavirenz